Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7794

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7794). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907794)

Losartan Potassium 25 mg film-coated tablets packaging label from A-S Medication Solutions. The label includes NDC 50090-7794-0 and quantity of 30 tablets. Storage instructions specify 68 to 77 degrees Fahrenheit and protection from light.*

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with the primary endpoint over months of study for Atenolol and Losartan Potassium. The x-axis shows study month up to 66 months, and the y-axis shows percent of patients up to 16%. The graph legend differentiates Atenolol with a dashed line and Losartan Potassium with a solid line. The graph notes an adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients affected, ranging from 0 to 8%. Two lines depict the data: a dashed line for Atenolol and a solid line for Losartan potassium. The graph notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

A forest plot comparing the event rates and hazard ratios for Losartan Potassium versus Atenolol in various patient subgroups. It displays primary composite outcomes and stroke (fatal/non-fatal) outcomes across age, gender, race, isolated systolic hypertension (ISH), diabetes status, and history of cardiovascular disease, with hazard ratios and confidence intervals indicating risk favorability between the two treatments.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

A line graph depicting the percentage of patients with an event over 48 months, comparing Losartan Potassium to placebo. The vertical axis shows percentage of patients, while the horizontal axis displays time in months. A solid line represents Losartan Potassium, and a dashed line represents placebo, illustrating a risk reduction of 16.1% with Losartan Potassium (p=0.022).*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

Chemical structure diagram of Losartan Potassium, showing the molecular arrangement of atoms including chlorine, nitrogen, oxygen, potassium ion, and carbon-based rings, corresponding to the active ingredient in Losartan Potassium 25 mg tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.